Guizhounli Pharmaceutical Co (SHSE:603439) Total Liabilities : ¥1,221 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co Total Liabilities?

Guizhounli Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 was ¥1,221 Mil.

Guizhounli Pharmaceutical Co's quarterly Total Liabilities declined from Dec. 2023 (¥1,211.10 Mil) to Mar. 2024 (¥1,155.51 Mil) but then increased from Mar. 2024 (¥1,155.51 Mil) to Jun. 2024 (¥1,220.51 Mil).

Guizhounli Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥372.93 Mil) to Dec. 2022 (¥578.40 Mil) and increased from Dec. 2022 (¥578.40 Mil) to Dec. 2023 (¥1,211.10 Mil).

Guizhounli Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co Total Liabilities Chart

Guizhounli Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

79.72

276.91

372.93

578.40

1,211.10

Guizhounli Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															533.28	551.91	1,211.10	1,155.51	1,220.51

Guizhounli Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Guizhounli Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	839.01	+	(254.318	+	117.77
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,211

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2920.451	-	1709.353
	=	1,211

Guizhounli Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	865.157	+	(232.181	+	123.176
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,221

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	2997.611	-	1777.098
	=	1,221

Guizhounli Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Guizhounli Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000

Website

http://www.gz-sanli.com

Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.

Executives

Zhang Hong Yu	Directors, senior managers
Wang Yi	senior management
Zhang Qian Fan	Directors, senior managers
Sheng Yong Jian	Director

Guizhounli Pharmaceutical Co Headlines

No Headlines